Preliminary Data in Faridoxorubicin Phase 1b Trial

Avacta Group PLC

08 December 2025

 

Avacta Group plc

("Avacta", the "Group" or the "Company")

Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort

LONDON and PHILADELPHIA - December 8, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, expects to announce initial Faridoxorubicin Phase 1b data in the salivary gland cancer indication on December 17, 2025. A presentation will be made available via the Investor Meet Platform on December 17, 2025, at 10:00 AM GMT. The link to view the presentation is below. Investors can register for the webinar and submit questions through the platform link below at any time before the presentation.

https://www.investormeetcompany.com/avacta-group-plc/register

-Ends-

For further information from Avacta, please contact:

Avacta Group plc Christina Coughlin, Chief Executive Officer	https://avacta.com/ via ICR Healthcare
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden	www.peelhunt.com
Zeus (Joint Broker) James Hornigold / George Duxberry Dominic King	www.zeuscapital.co.uk
ICR Healthcare (Europe/UK media and investors) Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert	[e-mail]
Investor Contact Renee Leck THRUST Strategic Communications	[e-mail]
Media Contact Carly Scaduto THRUST Strategic Communications	[e-mail]

About Avacta - www.avacta.com

Avacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION^®. The pre|CISION^® platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.

About pre|CISION^®

The key aspect of pre|CISION^® is its peptide drug conjugates (PDC) technology.  The combination of the cancer drug and the proprietary cleavable peptide (the PDC) is inert and incapable of entering cells and killing them until the peptide is specifically released within the tumor. The active payload in the pre|CISION^® PDC is released when the PDC comes into contact with the common tumor-associated protein, known as fibroblast activation protein (FAP), in the tumor. The release of the payload from the pre|CISION^® product directly in the tumor results in higher concentration of the drug at the tumor and lower blood and healthy tissue levels than standard systemic administration, offering the potential to improve efficacy and patient tolerability.

 

END